FDA panel unanimously backs Gilead's hepatitis C drug sofosbuvir

WASHINGTON (Reuters) - A federal advisory panel recommended on Friday that U.S. health regulators approve Gilead Sciences Inc's experimental hepatitis C drug sofosbuvir. The panel voted 15 to 0 in favor of approval of the drug in patients with two variants of the liver-damaging disease - genotype 2 and genotype 3 - in combination with an existing treatment, ribavirin. If approved, it would be the first all-oral treatment for genotypes 2 and 3. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/fda-panel-unanimously-backs-gileads-hepatitis-c-drug-185457018--finance.html